Heart failure & cardiomyopathies

Clinical Outcomes With Personalized Accelerated Physiologic Pacing in Heart Failure With Preserved Ejection Fraction: Follow-up of the myPACE Trial

JAMA CardiolPublished Observational extension of the myPACE randomised clinical trial

Authors' conclusion

In this observational clinical events analysis of the myPACE trial, analysis by ITT did not achieve statistical significance between study arms. However, PP analysis showed that personalized accelerated physiologic pacing was associated with a slower accrual of adverse clinical events compared with the standard 60-bpm setting.

Study context

Population
Patients with stage B or C heart failure with preserved ejection fraction (HFpEF) and preexisting physiologic pacemakers, University of Vermont Medical Center87 in per-protocol (PP) analysis
Participants
100 patients
Comparison
Personalized accelerated pacing vs 60 bpm
  • myPACEn = 48
  • Usual caren = 52reference
Primary endpoint
Accrual of first and recurrent adverse clinical events (urgent visits or hospitalizations for HF or AF, MI, stroke, or death)
Follow-up
Up to 4 years
Methodological detailsopen-label follow-up, single-centre, ITT and prespecified per-protocol analyses, Results primarily driven by HF-related events
  • Open-label follow-up
  • Single-centre
  • ITT and prespecified per-protocol analyses
  • Results primarily driven by HF-related events

Primary result

As reported in the abstract

Event accrual (ITT)

LWYY

0.48

95% CI 0.22–1.06P = 0.07

ITT

LWYY

0.16

95% CI 0.04–0.67P = 0.01

prespecified PP (n = 87): 5 vs 31 events

myPACE

15

events

Usual care

33

events

Secondary outcomes

OutcomeHR for first adverse clinical event (95% CI)P value
Event-free survival (ITT)Intention-to-treat0.63 (0.31–1.29)P = 0.20
Event-free survival (PP)Longer event-free survival with myPACE0.30 (0.11–0.80)P = 0.02
  • Event-free survival (PP): prespecified per-protocol analysis (n = 87)

Original publication

Clinical Outcomes With Personalized Accelerated Physiologic Pacing in Heart Failure With Preserved Ejection Fraction: Follow-up of the myPACE Trial. JAMA Cardiol. Published 1 October 2025. doi:10.1001/jamacardio.2025.2827

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.